



Dear Valued Customer,

This letter summarizes Johnson & Johnson Vision's approach related to the marketing and distribution of ACUVUE® Theravision® with Ketotifen (the "Product").

As announced in April 2021, Health Canada became the second regulatory authority to approve the Product; the first combination contact lens that provides vision correction and an antihistamine drug to help relieve symptoms for people experiencing itchy allergy eyes¹.

Health Canada has designated the Product as a medical device, in accordance with the below:

Medical Device Licence No.: 106027
Device first issue date: 2021-04-08
Licence Name: ACUVUE THERAVISION WITH KETOTIFEN

Since the Product includes a prescription drug, Johnson & Johnson Vision has designated that the Product may only be dispensed by Optometrists and Ophthalmologists in Canada. This decision was made carefully after a thorough review in the provinces where the Product will be available for sale. Through this comprehensive review, Johnson & Johnson Vision determined that opticians may not have the requisite expertise or training to safely dispense the Product to patients. This decision is consistent with Johnson & Johnson Vision's Credo whereby patient safety is paramount.

Johnson & Johnson Vision is excited to expand the availability of ACUVUE® Theravision® in 2022, via an early access launch to reach even more patients. Should you wish to learn more about this exciting new technology, please contact your Johnson & Johnson Vision sales representative or visit jnvisionpro.ca/products/acuvue-theravision.

Regards

A handwritten signature in black ink, appearing to read "Ted Lachmansingh".

Ted Lachmansingh
Business Director, Canada
Johnson & Johnson Vision Care division of Johnson & Johnson Inc.

1. JJV Data on File 2019. Mechanism of action, formulation, and comfort of ACUVUE® Theravision® with Ketotifen.

Important Safety Information: ACUVUE® Theravision® with Ketotifen contact lenses are available by prescription only for patients who require vision correction and experience ocular allergic itch due to allergic conjunctivitis. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness, narrow angle glaucoma or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care division of Johnson & Johnson Inc., or by calling 1-800-267-5098, or by visiting www.jnvisionpro.ca.

© Johnson & Johnson Vision Care division of Johnson & Johnson Inc. 2021 PP2021AVT4192

Johnson & Johnson Vision Care division of Johnson & Johnson Inc.,
200 Whitehall Drive, Markham, ON L3R 0T5